Received: April 28, 2021 Accepted: July 11, 2021

J-STAGE Advance published date: February 9, 2022

DOI: <https://doi.org/10.37737/ace.22006>

Effect of dobutamine on patients with septic shock: A retrospective nationwide study

Authors

Shotaro Aso¹, M.D., M.P.H., Ph.D.

Hiroki Matsui², M.P.H.

Kiyohide Fushimi³, M.D., Ph.D.

Hideo Yasunaga², M.D., Ph.D.

¹Department of Biostatistics & Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

²Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

³Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan.

- 15 **Correspondence to** Shotaro Aso, MD, MPH, PhD, Department of Biostatistics &
16 Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo,
17 Bunkyo-ku, Tokyo, 113-0033, Japan
18 email: s_aso@m.u-tokyo.ac.jp; Tel: +81-3-3815-5411; Fax: +81-3-5800-9175
19 **Keywords:** septic shock, dobutamine, mortality.

20 Abstract

21 **Background:** Dobutamine is administered to patients with hypoperfusion associated with
22 septic shock; however, its effect on mortality of septic shock remains unknown. We used a
23 national inpatient database to investigate the effect of dobutamine on patients with septic
24 shock.

25 **Methods:** Adults with septic shock who received ≥ 30 mL/kg fluid and ≥ 10 μ g/min
26 noradrenaline and either vasopressin or adrenaline within 1 day after admission from 1 July
27 2010 to 31 March 2016 were identified by searching the Japanese Diagnosis Procedure
28 Combination database. Stabilized inverse probability weighting analysis using propensity
29 scores was performed to compare all-cause 28-day mortality and length of stay between
30 patients who had and had not received dobutamine.

31 **Results:** Of 4747 eligible patients, 1259 had received dobutamine and 3488 had not. All-
32 cause 28-day mortality did not differ significantly between the groups (risk difference, 0.1%;
33 95% confidence interval [CI], -3.3 to 3.4; $P = 0.975$). Receipt of dobutamine was
34 significantly associated with longer hospital stay (difference, 3.8; 95% CI, 0.5–7.2; $P =$
35 0.024). Subgroup analysis showed that receipt of dobutamine was not significantly associated
36 with length of stay in patients with cardiovascular disease (difference, -5.1 days; 95% CI,
37 -11.7 to 1.5; $P = 0.133$), or those who received ≥ 20 μ g/min noradrenaline (difference, 0.5
38 days; 95% CI, -6.8 to 7.7; $P = 0.900$).

39 **Conclusions:** Overall all-cause 28-day mortality in patients with septic shock did not
40 significantly differ between patients who had and had not received dobutamine; however,
41 receipt of dobutamine was significantly associated with longer hospital stay.
42

43 **Introduction**

44 Septic shock, a life-threatening condition, is caused by a host response to infection. Appropriate
45 management of septic shock in its initial stage is important in reducing mortality. Treatments
46 for septic shock include antimicrobial therapy and source control, adequate fluid resuscitation,
47 use of noradrenaline as the first-line vasopressor, use of vasopressin or adrenaline, and use of
48 corticosteroids [1]. Although treatments for septic shock have been standardized and used
49 extensively, its mortality remains high ($\geq 40\%$) [2].

50 Dobutamine, an inotropic agent, increases cardiac output through augmentation of stroke
51 volume and may improve tissue hypoperfusion of patients with septic shock by increasing
52 oxygen delivery[3]. Surviving sepsis campaign guidelines recommend early goal-directed
53 therapy, including use of dobutamine[4]. However, early goal-directed therapy did not reduce
54 mortality in several published randomized controlled studies[5–7]. The guidelines continue to
55 recommend use of dobutamine in patients with septic shock and persistent hypoperfusion
56 despite adequate fluid loading and use of high-dose vasopressors[1].

57 Two previous studies have investigated the effect of inotropes on septic shock[8,9]. One
58 underpowered study showed that noradrenaline plus dobutamine was not associated with
59 reducing mortality compared with adrenaline. The interventions in that study were
60 heterogeneous, preventing it from determining the effect of dobutamine. The other, a
61 randomized controlled study investigating the effect of levosimendan in patients with septic

shock, found that administration of levosimendan did not improve SOFA (Sequential Organ Failure Assessment) scores. Levosimendan is a calcium-sensitizing inotrope that increases the force of myocardial contraction without increasing myocardial oxygen consumption, in contrast with catecholamines[10]. Thus, it remains unclear whether dobutamine reduces mortality of septic shock. The aim of this study was to investigate the effect of dobutamine in patients septic shock by using a national inpatient database in Japan.

Methods

Data source

Inpatient data were extracted from the Japanese Diagnosis Procedure Combination database. More than 1200 acute care hospitals voluntarily contribute to this database, which covers more than 80% of all tertiary-care emergency hospitals in Japan. The database includes data on approximately seven million inpatients, representing approximately 50% of all discharges from acute care hospitals in Japan. These data include hospital identification numbers, patients' sexes and ages; body weights and heights; conscious state on admission; dates of hospitalization and discharge; main diagnoses; pre-existing comorbidities on admission, and complications that occurred during hospitalization recorded with International Classification of Diseases, tenth revision (ICD-10) codes and text in Japanese; surgical and nonsurgical procedures and dates on which the procedures were performed; dates and doses of drugs or blood products

administered during the hospitalization; and discharge status. Recorded diagnoses and procedures in the database have been validated in a previous study[11], which found that the specificity of diagnoses exceeded 96%, sensitivity of diagnoses was 50%–80%, and the specificity and sensitivity of procedures both exceeded 90%.

The institutional Review Board of The University of Tokyo approved this study. The requirement for informed consent was waived because only anonymized data were studied.

Patient selection

In this study, data from 1 July 2010 to 31 March 2016 were used. Data on patients aged ≥ 15 years who were diagnosed with sepsis (Supplement 1) and had received antibiotics, and ≥ 30 mL/kg fluid, and ≥ 10 μ g/min noradrenaline, and either vasopressin or adrenaline within 1 day after admission were included[1]. Patients who had undergone cardiopulmonary resuscitation within 1 day after admission were excluded because adrenaline was administered during cardiopulmonary resuscitation.

The patients were divided into two groups: (I) patients who received dobutamine within 1 day after admission (dobutamine group); and (II) those who did not receive dobutamine within 1 day after admission (control group).

Baseline characteristics and outcomes

100 Baseline characteristics included the following: age; sex; body mass index (BMI); conscious
 101 state on admission; Charlson comorbidity index (CCI); fiscal year; comorbidities including
 102 acute respiratory distress syndrome (ICD-10 codes: J80), cardiovascular disease (I05–09, I11.0,
 103 I13.2, I20–25, I34–37, I39, I42–45, I47–48, I49.1–5, I49.8, I49.9, I50, I51.1, I51.2, I51.8, I51.9),
 104 chronic kidney disease (N18), pulmonary disease (J41–47, J84.1, J84.8, J84.9), and
 105 hematologic disorder (C81–85, C88, C90–96, D46–47, D60, D70, D80); surgery for infection
 106 within 1 day after admission (Supplement 2); use of mechanical ventilation within 1 day after
 107 admission; continuous renal replacement therapy within 1 day after admission; intermittent
 108 renal replacement therapy within 1 day after admission; rehabilitation within 1 day after
 109 admission; and administered drugs within 1 day after admission including vasopressin,
 110 adrenaline, corticosteroids, dopamine, milrinone, sodium bicarbonate, dexmedetomidine,
 111 propofol, midazolam, neuromuscular blockers, morphine, fentanyl, landiolol, amiodarone,
 112 proton pump inhibitors, H2-blockers, penicillin (ampicillin or ampicillin/sulbactam), cephem
 113 (first, second, or third generation cephem, which are ineffective against *Pseudomonas*-group,
 114 or cephamycin), azithromycin, cotrimoxazole, anti-methicillin-resistant-*Staphylococcus*
 115 *aureus* drugs (vancomycin, teicoplanin, daptomycin, linezolid, quinupristin/dalfopristin, or
 116 arbekacin), anti-*Pseudomonas*-group drugs (third generation cephem with *Pseudomonas*-group
 117 activity, fourth generation cephem, aminoglycoside, carbapenem, new quinolone, piperacillin,
 118 piperacillin/tazobactam, colistin, or monobactam), anti-fungal drugs (azoles, amphotericin B,

or echinocandins); and total amounts of crystalloid solution, albumin preparation, red blood cells, fresh frozen plasma, and platelet concentrate. Conscious state on admission was evaluated using Japan Coma Scale (JCS) scores[12]. The JCS is widely used in Japan and JCS and Glasgow Coma Scale scores correlate well[13,14]. A JCS score of 0 indicates alertness, 1 to 3 indicates wakefulness without any stimuli, 10 to 30 indicates arousal in response to some stimuli, and 100 to 300 indicates coma. The CCI, a well-validated scoring system for disease burden, also predicts mortality well and has been widely used as a factor in risk adjustment[15]. CCI scores were classified into five groups: 0, 1, 2, 3–5, and ≥ 6 . Doses of noradrenaline were classified into two groups: 10–20 $\mu\text{g}/\text{min}$, and $\geq 20 \mu\text{g}/\text{min}$. To adjust for the severity of patients' conditions, all components of SOFA scores except for liver dysfunction were selected as baseline characteristics; namely, use of mechanical ventilation, continuous renal replacement therapy, conscious state on admission (JCS), and transfusion of platelet concentrate[16]. The primary outcome was all-cause 28-day mortality. The secondary outcome was length of stay.

Statistical analysis

Stabilized inverse probability weighting (IPW) analysis using propensity scores (PS) to balance the patient backgrounds between the dobutamine and control groups was performed. To calculate the PS for receipt of dobutamine, a multivariable logistic regression model including

baseline characteristics was used. C-statistics were calculated to evaluate the model's discrimination of receipt of dobutamine. Patients who received dobutamine were weighted by stabilized IPW calculated as $p(N)/PS$, whereas patients who did not receive dobutamine were weighted by $(1-p(N))/(1-PS)$, where $p(N)$ is the probability of receiving dobutamine in this patient cohort and PS is the individual's PS for receiving dobutamine[17]. Average treatment effect was estimated using stabilized IPW. Standardized differences for covariates were calculated; absolute standardized differences of less than 10% indicate good balance[18,19]. Continuous variables are presented as median and interquartile ranges (IQR), whereas categorical variables are presented as number and proportions. Averages of continuous variables were compared using *t*-tests, and proportions of categorical variables were compared using χ^2 tests. The threshold for significance was $P < 0.05$. All analyses were performed using STATA/MP version 15.0 software (STATA, College Station, TX, USA).

Results

We identified 5581 patients aged ≥ 15 years who had received antibiotics and ≥ 30 mL/kg fluid and ≥ 10 $\mu\text{g}/\text{min}$ noradrenaline and either vasopressin or adrenaline within 1 day after admission. Figure 1 is a flow chart of patient selection. There were 4747 eligible patients, 1259 of whom were assigned to the dobutamine group and the remaining 3488 to the control group. Table 1 shows patients' baseline characteristics according to study groups prior to and after

157 IPW. Patients in the dobutamine group were more likely to be male; have cardiovascular
158 disease; and receive mechanical ventilation, adrenaline, dopamine, albumin preparations,
159 dexmedetomidine, propofol, midazolam, milrinone, neuromuscular blocker, sodium
160 bicarbonate, and amiodarone. Fiscal years were imbalanced. After stabilized IPW analysis, all
161 variables were well-balanced.

162 The overall all-cause 28-day mortality was 36.5% (1732/4747), and the average length of stay
163 was 25 days (IQR, 8–51). All-cause 28-day mortality was not significantly higher in the
164 dobutamine than the control group (38.7% vs. 35.7%, $P = 0.059$). Length of stay was 26 days
165 (IQR, 9–54) in the dobutamine group and 25 days (IQR, 8–51) in the control group.

166 In the stabilized IPW analysis, the C-statistic was 0.66. There were no significant differences
167 between the dobutamine and control groups in terms of all-cause 28-day mortality (risk
168 difference, 0.1%; 95% confidence interval [CI], -3.3 to 3.4 ; $P = 0.975$) (Table 2). Length of
169 stay was significantly longer in the dobutamine than the control group (difference, 3.8; 95%
170 CI, 0.5 to 7.2 ; $P = 0.024$) (Table 3).

171 In the subgroup analysis, use of dobutamine was not significantly associated with all-cause 28-
172 day mortality, irrespective of past history of cardiovascular disease or dose of noradrenaline
173 (Table 2). Use of dobutamine was not significantly associated with length of stay in patients
174 with cardiovascular disease (difference, -5.1 days; 95% CI, -11.7 to 1.5 ; $P = 0.132$), or receipt
175 of ≥ 20 $\mu\text{g}/\text{min}$ noradrenaline (difference, 0.5 days; 95% CI, -6.8 to 7.7 ; $P = 0.898$) (Table 3).

176

177 **Discussion**

178 Our study showed all-cause 28-day mortality in patients with septic shock did not differ
179 significantly between those who did and did not receive dobutamine. Use of dobutamine was
180 associated with longer hospital stay. Regardless of past history of cardiovascular disease, use
181 of dobutamine was not associated with all-cause 28-day mortality of patients with septic shock.
182 In our study, use of dobutamine was associated with longer length of stay without improving
183 all-cause 28-day mortality. Dobutamine for septic shock may increase cardiac output and raise
184 mean arterial pressure of patients with tissue hypoperfusion; however, the effects of
185 dobutamine may be temporary in such patients. In the present study, use of dobutamine was
186 associated with prolonged length of stay but not with reduction in mortality of patients with
187 septic shock. Unlike the overall findings, use of dobutamine was not associated with longer
188 length of stay in patients with cardiovascular disease or those who received high-dose
189 noradrenaline. One possible explanation for this apparent discrepancy is that dobutamine could
190 not improve the cardiac output of patients with cardiovascular disease or increase the mean
191 arterial pressure of those receiving high-dose noradrenaline. Another possible explanation is
192 that adverse effects of dobutamine, such as ventricular arrhythmia and vasodilation, affected
193 patients with cardiovascular disease or receiving high-dose noradrenaline[3].
194 The present study had several limitations. First, the data were provided per day unit. Data on

the clock time at which dobutamine was started, and the sequence of vasopressor and dobutamine were not available. Second, the database did not include indicators of cardiac output and tissue hypoperfusion. The guidelines state that the best way to determine when to use dobutamine is by monitoring the response of indices of perfusion to measured increases in cardiac output. The absence of indicators of cardiac output and tissue hypoperfusion may have resulted in selection bias. Additionally, patients with normal cardiac function were unlikely to receive dobutamine and it may have had little effect in such patients.

Conclusions

Our stabilized IPW analyses using a national inpatient database showed that dobutamine was not associated with reducing mortality. Further studies are required to further investigate the effect of dobutamine on mortality.

208 **References**

- 209 1 Rhodes A, Evans LE, Alhazzani W, *et al.* Surviving Sepsis Campaign: International
210 Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med*
211 2017;**45**:486–552. doi:10.1097/CCM.0000000000002255
- 212 2 Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus
213 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;**315**:801–10.
214 doi:10.1001/jama.2016.0287
- 215 3 Ruffolo R. The pharmacology of dobutamine. *Am J Med Sci* 1987;**294**:244–8.
- 216 4 Dellinger RP, Levy MM, Rhodes A, *et al.* Surviving sepsis campaign: international
217 guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med*
218 2013;**41**:580–637. doi:10.1097/CCM.0b013e31827e83af
- 219 5 Yealy DM, Kellum J a, Huang DT, *et al.* A randomized trial of protocol-based care for
220 early septic shock. *N Engl J Med* 2014;**370**:1683–93. doi:10.1056/NEJMoa1401602
- 221 6 Bailey M, Bellomo R, Peter A, *et al.* Goal-Directed Resuscitation for Patients with
222 Early Septic Shock. *N Engl J Med* 2014;**371**:1946–506. doi:10.1056/NEJMoa1404380
- 223 7 Mouncey PR, Osborn TM, Power GS, *et al.* Trial of early, goal-directed resuscitation
224 for septic shock. *N Engl J Med* 2015;**372**:1301–11. doi:10.1056/NEJMoa1500896
- 225 8 Annane D, Vignon P, Renault A, *et al.* Norepinephrine plus dobutamine versus
226 epinephrine alone for management of septic shock: a randomised trial. *Lancet*

- 2007;**370**:676–84. doi:10.1016/S0140-6736(07)61344-0
- 9 Gordon AC, Perkins GD, Singer M, *et al.* Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med* 2016;**375**:1638–48. doi:10.1056/NEJMoa1609409
- 10 Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. *Anesthesiology* 2006;**104**:556–69. doi:10.1097/00000542-200603000-00024
- 11 Yamana H, Moriwaki M, Horiguchi H, *et al.* Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. *J Epidemiol* 2017;**27**:476–82. doi:10.1016/j.je.2016.09.009
- 12 Ohta T, Waga S, Handa H, *et al.* New grading of level of disordered consciousness (author’s translation). *No shinkei geka* 1974;**2**:623–7.
- 13 Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome—reintroduction of Japan Coma Scale: a cohort study. *BMJ Open* 2013;**3**:e002736. doi:10.1136/
- 14 Ono K, Wada K, Takahara T, *et al.* Indications for Computed Tomography in Patients With Mild Head Injury. *Neurol Med Chir* 2007;**47**:291–8.
- 15 Quan H, Li B, Couris CM, *et al.* Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;**173**:676–82. doi:10.1093/aje/kwq433

- 246 16 Vincent JL, Moreno R, Takala J, *et al.* The SOFA (Sepsis-related Organ Failure
247 Assessment) score to describe organ dysfunction/failure. On behalf of the Working
248 Group on Sepsis-Related Problems of the European Society of Intensive Care
249 Medicine. *Intensive Care Med* 1996;**22**:707–
250 10.<http://www.ncbi.nlm.nih.gov/pubmed/8844239>
- 251 17 Xu S, Ross C, Raebel MA, *et al.* Use of stabilized inverse propensity scores as weights
252 to directly estimate relative risk and its confidence intervals. *Value Heal* 2010;**13**:273–
253 7. doi:10.1111/j.1524-4733.2009.00671.x
- 254 18 Austin PC. Balance diagnostics for comparing the distribution of baselinecovariates
255 between treatment groups in propensity-scorematched samples. *Stat Med*
256 2009;**28**:3083–107. doi:10.1002/sim
- 257 19 Austin PC, Stuart EA. Moving towards best practice when using inverse probability of
258 treatment weighting (IPTW) using the propensity score to estimate causal treatment
259 effects in observational studies. *Stat Med* 2015;**34**:3661–79. doi:10.1002/sim.6607
260

261 **Figure legend**

262 **Figure. 1** Flow chart of patient selection

263 IPW; inverse probability of weighting.

264

265 Table 1. Patient characteristics according to control and dobutamine groups prior to adjustment and after stabilized inverse probability weighting analysis

Variables	Unadjusted group			Stabilized IPW group		
	Control group	Dobutamine group	Standardized difference (%)	Control group	Dobutamine group	Standardized difference (%)
Sex (male), n (%)	1963 (56.3)	777 (61.7)	11.1	(57.4)	(57.4)	0.1
Age, years (SD)	71.2 (13.4)	70.9 (13.8)	2.6	71.3 (18.2)	70.3 (34.5)	3.6
Body Mass Index, n (%)			7.2			1.0
18.50–24.99	1911 (54.8)	690 (54.8)		(57.3)	(57.0)	
18.50<	799 (22.9)	293 (23.3)		(24.1)	(24.3)	
25.00–29.99	473 (13.6)	185 (14.7)		(14.6)	(14.8)	
≥30.00	138 (4.0)	47 (3.7)		(4.1)	(4.0)	
Missing	167 (4.8)	44 (3.5)				
Japan coma scale, n (%)			4.8			1.8
0 (alert)	1312 (37.6)	485 (38.5)		(37.8)	(37.1)	
1-digit (wakefulness)	923 (26.5)	336 (26.7)		(26.7)	(26.6)	
2-digit (somnolence)	486 (13.9)	155 (12.3)		(13.7)	(13.9)	
3-digit (coma)	767 (22.0)	283 (22.5)		(21.8)	(22.4)	
Charlson comorbidity index, n (%)			7.5			2.4
0	2193 (62.9)	762 (60.5)		(62.2)	(62.5)	
1	334 (9.6)	128 (10.2)		(9.8)	(9.7)	
2	686 (19.7)	265 (21.0)		(19.9)	(19.9)	
3–5	184 (5.3)	79 (6.3)		(5.5)	(5.2)	
≥6	91 (2.6)	25 (2.0)		(2.6)	(2.8)	
Fiscal year, n (%)			14.5			3.1
2010	155 (4.4)	79 (6.3)		(4.9)	(5.3)	

2011	303 (8.7)	139 (11.0)		(9.2)	(9.5)	
2012	428 (12.3)	165 (13.1)		(12.2)	(12.5)	
2013	590 (16.9)	230 (18.3)		(17.0)	(16.8)	
2014	972 (27.9)	316 (25.1)		(27.6)	(27.6)	
2015	1040 (29.8)	330 (26.2)		(29.2)	(28.3)	
Cardiovascular disease	526 (15.1)	315 (25.0)	25.0	(17.4)	(17.3)	0.3
Acute respiratory distress syndrome, n (%)	127 (3.6)	67 (5.3)	8.1	(4.1)	(4.1)	0.0
Chronic kidney disease, n (%)	182 (5.2)	87 (6.9)	7.1	(5.8)	(5.6)	0.9
Pulmonary disease, n (%)	113 (3.2)	47 (3.7)	2.7	(3.4)	(3.2)	1.1
Hematologic disorder, n (%)	100 (2.9)	38 (3.0)	0.9	(2.9)	(3.0)	0.5
Dose of noradrenaline, n (%)						1.2
10–20 µg/min	2795 (80.1)	959 (76.2)	9.6	(79.1)	(78.6)	
≥20 µg/min	693 (19.9)	300 (23.8)		(20.9)	(21.4)	
Adrenaline, n (%)	1238 (35.5)	548 (43.5)	16.5	(37.5)	(37.2)	0.6
Vasopressin, n (%)	2644 (75.8)	916 (72.8)	7.0	(75.1)	(75.4)	0.8
Dopamine, n (%)	1295 (37.1)	532 (42.3)	10.5	(38.5)	(39.3)	1.7
Milrinone	79 (2.3)	66 (5.2)	15.7	(3.0)	(3.1)	0.6
Landiolol	394 (11.3)	138 (11.0)	1.1	(11.4)	(11.9)	1.6
Amiodarone	87 (2.5)	61 (4.8)	12.5	(3.0)	(2.9)	0.4
Corticosteroids, n (%)	2122 (60.8)	820 (65.1)	8.9	(62.6)	(63.7)	2.3
Mechanical ventilation, n (%)	2775 (79.6)	1088 (86.4)	18.3	(81.4)	(82.3)	2.3
Continuous renal replacement therapy, n (%)	1210 (34.7)	595 (47.3)	25.8	(38.4)	(39.0)	1.2
Intermittent renal replacement therapy, n (%)	129 (3.7)	30 (2.4)	7.7	(3.2)	(3.4)	0.9
Sodium bicarbonate, n (%)	1402 (40.2)	645 (51.2)	22.3	(43.2)	(43.4)	0.6

Total infusion of crystalloid, mL (SD)	14245 (12346)	15049 (10583)	−7.0	14503 (13246)	14484 (12218)	0.2
Total infusion of albumin preparation, mL (SD)	484 (819)	597 (809)	−13.8	520 (989)	523 (701)	0.4
Total transfusion of fresh frozen plasma, mL (SD)	634 (4462)	738 (1109)	−3.2	667 (4269)	648 (984)	0.6
Total transfusion of platelet concentrate, mL (SD)	1276 (17092)	1526 (3045)	−2.0	108 (1316)	104 (221)	0.4
Total transfusion of red blood cell concentrate, mL (SD)	960 (12265)	1118 (4293)	−1.7	559 (6492)	515 (2060)	0.9
Dexmedetomidine, n (%)	902 (25.9)	406 (32.2)	14.1	(27.6)	(28.1)	0.9
Propofol, n (%)	1481 (42.5)	612 (48.6)	12.4	(43.9)	(43.4)	0.9
Midazolam, n (%)	1653 (47.4)	735 (58.4)	22.1	(50.2)	(50.5)	0.6
Fentanyl, n (%)	2262 (64.9)	865 (68.7)	8.2	(65.9)	(66.3)	0.8
Morphine, n (%)	64 (1.8)	41 (3.3)	9.0	(2.2)	(2.2)	0.0
Neuromuscular blockers, n (%)	1817 (52.1)	744 (59.1)	14.1	(53.9)	(53.8)	0.2
Surgery, n (%)	1250 (35.8)	423 (33.6)	4.7	(35.4)	(35.7)	0.6
Proton pump inhibitors, n (%)	888 (25.5)	299 (23.7)	4.0	(24.7)	(24.3)	0.8
H2-blockers, n (%)	720 (20.6)	279 (22.2)	3.7	(21.2)	(21.3)	0.3
Penicillin, n (%)	395 (11.3)	162 (12.9)	4.7	(11.7)	(11.5)	0.8
Cephem, n (%)	816 (23.4)	348 (27.6)	9.8	(24.2)	(24.2)	0.0
Anti-methicillin-resistant <i>Staphylococcus aureus</i> drugs, n (%)	906 (26.0)	367 (29.2)	7.1	(26.6)	(26.4)	0.4
Anti- <i>Pseudomonas</i> group drugs, n (%)	3122 (89.5)	1121 (89.0)	1.5	(89.7)	(90.1)	1.5
Azithromycin, n (%)	195 (5.6)	81 (6.4)	3.5	(5.7)	(5.8)	0.5
Cotrimoxazole, n (%)	31 (0.9)	13 (1.0)	1.5	(1.0)	(1.0)	0.4
Anti-fungal drugs, n (%)	214 (6.1)	86 (6.8)	2.8	(6.5)	(6.2)	0.9
Rehabilitation, n (%)	232 (6.7)	59 (4.7)	8.5	(6.1)	(5.9)	0.9

266 IPW; inverse probability of weighting.

Table 2. All-cause 28-day mortality in patients who did and did not receive dobutamine

	Risk difference	95% confidence interval			P value
Crude	3.0	−0.1	to	6.1	0.059
stabilized IPW	0.1	−3.1	to	3.2	0.975
Subgroup analysis					
Cardiovascular disease					
Yes	4.3	−2.7	to	11.5	0.225
No	−0.9	−4.6	to	2.9	0.660
Dose of noradrenaline					
10–20 µg/min	0.0	−3.8	to	3.8	0.997
≥ 20 µg/min	0.1	−7.2	to	7.4	0.980

IPW; inverse probability of weighting.

Table 3. Length of stay in patients who did and did not receive dobutamine

	Difference	95% confidence interval			P value
Crude	4.0	1.1	to	7.0	0.007
stabilized IPW	3.8	0.5	to	7.1	0.024
Subgroup analysis					
Cardiovascular disease					
Yes	-5.1	-11.7	to	1.5	0.132
No	5.7	1.9	to	9.5	0.003
Dose of norepinephrine					
10–20 µg/min	4.7	1.0	to	8.5	0.013
≥ 20 µg/min	0.5	-6.8	to	7.7	0.898

IPW; inverse probability of weighting.

Figure. 1 Flow chart of patient selection

IPW; inverse probability of weighting.

ICD-10: International Classification of Diseases, Tenth Revision.

Supplementary Table 2. Japanese procedure codes that denote surgery for infection

[illegible]